Moleculera BiosciencesPipeline
Power of precision medicine
We believe in the power of precision medicine and that when the root cause of chronic, debilitating disorders is identified and treated, patients can live longer, healthier lives. At Moleculera Biosciences, our team is committed to developing and commercializing groundbreaking autoantibody tests that identify an underlying autoimmune etiology in patients with difficult-to-treat conditions, including neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease, so clinicians can direct treatment to the underlying root and improve patient outcomes.
Bringing hope and healing to patients with difficult-to-treat disorders
Moleculera Biosciences is advancing a robust pipeline of several autoantibody tests that aim to assist with the diagnosis and treatment of immune-mediated disorders, including neuropsychiatric and cardiovascular disorders and Alzheimer’s disease.
The company’s signature test, the Autoimmune Brain Panel™, has been utilized by more than 2,800 clinicians worldwide to help identify an underlying infection-triggered autoimmune process in patients with psychiatric and/or neurologic symptoms, such as PANDAS and PANS, and assist with directing treatment. Moleculera expects to commercialize additional panels, including the Autoimmune Cardiovascular Panel™ for cardiovascular diseases such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis, as well as the Alzheimer’s Early Intervention Inflammatory Biomarker (AEIIB)™ panel, to identify and intervene in patients at an early stage before clinical symptoms appear.
